(Total Views: 668)
Posted On: 12/19/2021 12:14:08 PM
Post# of 36566
According to https://www.excellagen.com/comp-advantage the patent is attached to Excellagen (actual product).
Excellagen is owned/manufactured by Olaregen Therapeutix https://www.olaregen.com/
Olaregen Therapeutix is wholly owned by Generex https://www.crunchbase.com/organization/olaregen-therapeutix (the holding company)
So since Olaregen is a private company, its financials will remain private, but the holding company, Generex should/must? report any financial benefits it gets from its subsidiary (Olaregen) on their 10-Q/Ks.
Searching the last 10-Q https://www.sec.gov/Archives/edgar/data/10597...orm10q.htm on “Olaregen” the only income reference I could find was “Regarding the Company, sales of Olaregen's Excellagen have been significantly impacted by the COVID-19 pandemic”
So the question is; how much financial information is legally required to be revealed (10-Q/Ks) about a privately held subsidiary (Olaregen) to the publicly held (Generex) stockholders?
Excellagen is owned/manufactured by Olaregen Therapeutix https://www.olaregen.com/
Olaregen Therapeutix is wholly owned by Generex https://www.crunchbase.com/organization/olaregen-therapeutix (the holding company)
So since Olaregen is a private company, its financials will remain private, but the holding company, Generex should/must? report any financial benefits it gets from its subsidiary (Olaregen) on their 10-Q/Ks.
Searching the last 10-Q https://www.sec.gov/Archives/edgar/data/10597...orm10q.htm on “Olaregen” the only income reference I could find was “Regarding the Company, sales of Olaregen's Excellagen have been significantly impacted by the COVID-19 pandemic”
So the question is; how much financial information is legally required to be revealed (10-Q/Ks) about a privately held subsidiary (Olaregen) to the publicly held (Generex) stockholders?
(2)
(0)
